BACE1 and Alzheimer disease: The calculations of residue-based free energy decomposition suggest that the sidechains of residues L91, D93, S96, V130, Q134, W137, F169 and I179 play key roles in inhibitor–BACE1 binding, which provides a direction for future drug design toward the treatment of AD.